{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003405","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.813325+00:00","generated_at":"2026-05-24T09:35:38.421685+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal","bullets":["Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.","Phase 2 Tailwind study of inhaled AP-PA02 in NCFB showed statistically significant reduction of P.a. CFUs; well-tolerated.","Phase 1b/2a diSArm study of IV AP-SA02 for S. aureus bacteremia enrollment complete; topline data expected H1 2025.","Entered $10M secured credit agreement with Innoviva subsidiary at 14% interest, maturing March 2026; existing loans also extended."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003405","json":"https://secwatch.observer/filing/0001558370-25-003405.json","markdown":"https://secwatch.observer/filing/0001558370-25-003405.md","text":"https://secwatch.observer/filing/0001558370-25-003405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/0001558370-25-003405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/armp-20250320x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:35:38.421685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}